Posted by Michael Wonder on 20 Aug 2018
Proposal to list nintedanib (Ofev) and remove restrictions from tiotropium bromide (Spiriva)
20 August 2018 - PHARMAC is seeking feedback on a proposal to list nintedanib (Ofev) and remove the current funding restrictions from tiotropium (Spiriva and Spiriva Respimat) from 1 October 2018, through a provisional agreement with Boehringer Ingelheim.
Nintedanib would be funded, subject to funding restrictions, for the treatment of idiopathic pulmonary fibrosis. Some changes would also be made to the pirfenidone funding restrictions for clarity and to prevent concurrent use of pirfenidone and nintedanib.
A confidential net price reduction for tiotropium would occur in conjunction with the removal of funding restrictions. This change would mean that all funded long-acting muscarinic antagonist monotherapy inhalers would be available without Special Authority restrictions.
